Related Experiment Video
Updated: Jun 26, 2025
Eye Tracking Young Children with Autism
Published on: March 27, 2012
Eye-Tracking Biomarkers and Autism Diagnosis in Primary Care
Brandon Keehn1,2, Patrick Monahan3, Brett Enneking4
1Department of Speech, Language, and Hearing Sciences, Purdue University, West Lafayette, Indiana.
Insights
Eye-tracking biomarkers show promise for improving early autism diagnosis. Combining these with primary care practitioner (PCP) assessments significantly enhances diagnostic accuracy and accessibility in community settings.
Area of Science:
- Neurodevelopmental disorders
- Biomarkers in diagnostics
- Pediatric health
Background:
- Diagnostic delays and disparities in autism spectrum disorder (ASD) present a significant public health challenge.
- Integrating innovative tools into community-based models is crucial for early and equitable autism evaluation.
- Eye-tracking biomarkers offer a potential solution for improving the accuracy and accessibility of autism diagnostics.
Purpose of the Study:
- To assess the reliability of eye-tracking biomarkers in differentiating young children with and without autism in a primary care setting.
- To evaluate the impact of combining eye-tracking biomarkers with primary care practitioner (PCP) diagnosis and diagnostic certainty on diagnostic outcomes.
Main Methods:
- A prospective diagnostic study involving 146 children (aged 14-48 months) referred to Early Autism Evaluation (EAE) Hubs.
- Children underwent a blinded eye-tracking index test and follow-up expert evaluation.
- Primary outcomes included sensitivity and specificity of the eye-tracking test; secondary outcomes assessed an integrated approach with PCP input.
Main Results:
- A composite eye-tracking biomarker test showed 77.5% sensitivity and 77.3% specificity in identifying autism.
- An integrated model combining eye-tracking biomarkers, PCP diagnosis, and diagnostic certainty achieved 90.7% sensitivity and 86.7% specificity.
- Diagnostic outcomes were concordant with reference standards in 77% of cases with the biomarker alone and 90% with the integrated approach.
Conclusions:
- A composite eye-tracking biomarker is associated with clinical autism diagnosis in young children.
- An integrated diagnostic model incorporating eye-tracking, PCP diagnosis, and certainty significantly improves diagnostic sensitivity and specificity.
- This multimethod approach has the potential to enhance timely and accurate autism diagnosis within local communities.
Importance:
Finding effective and scalable solutions to address diagnostic delays and disparities in autism is a public health imperative. Approaches that integrate eye-tracking biomarkers into tiered community-based models of autism evaluation hold promise for addressing this problem.
Objective:
To determine whether a battery of eye-tracking biomarkers can reliably differentiate young children with and without autism in a community-referred sample collected during clinical evaluation in the primary care setting and to evaluate whether combining eye-tracking biomarkers with primary care practitioner (PCP) diagnosis and diagnostic certainty is associated with diagnostic outcome.
Design, Setting, And Participants:
Early Autism Evaluation (EAE) Hub system PCPs referred a consecutive sample of children to this prospective diagnostic study for blinded eye-tracking index test and follow-up expert evaluation from June 7, 2019, to September 23, 2022. Participants included 146 children (aged 14-48 months) consecutively referred by 7 EAE Hubs. Of 154 children enrolled, 146 provided usable data for at least 1 eye-tracking measure.
Main Outcomes And Measures:
The primary outcomes were sensitivity and specificity of a composite eye-tracking (ie, index) test, which was a consolidated measure based on significant eye-tracking indices, compared with reference standard expert clinical autism diagnosis. Secondary outcome measures were sensitivity and specificity of an integrated approach using an index test and PCP diagnosis and certainty.
Results:
Among 146 children (mean [SD] age, 2.6 [0.6] years; 104 [71%] male; 21 [14%] Hispanic or Latine and 96 [66%] non-Latine White; 102 [70%] with a reference standard autism diagnosis), 113 (77%) had concordant autism outcomes between the index (composite biomarker) and reference outcomes, with 77.5% sensitivity (95% CI, 68.4%-84.5%) and 77.3% specificity (95% CI, 63.0%-87.2%). When index diagnosis was based on the combination of a composite biomarker, PCP diagnosis, and diagnostic certainty, outcomes were concordant with reference standard for 114 of 127 cases (90%) with a sensitivity of 90.7% (95% CI, 83.3%-95.0%) and a specificity of 86.7% (95% CI, 70.3%-94.7%).
Conclusions And Relevance:
In this prospective diagnostic study, a composite eye-tracking biomarker was associated with a best-estimate clinical diagnosis of autism, and an integrated diagnostic model including PCP diagnosis and diagnostic certainty demonstrated improved sensitivity and specificity. These findings suggest that equipping PCPs with a multimethod diagnostic approach has the potential to substantially improve access to timely, accurate diagnosis in local communities.
More Related Videos
05:32Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
Published on: December 7, 2018
06:15Using the Visual World Paradigm to Study Sentence Comprehension in Mandarin-Speaking Children with Autism
Published on: October 3, 2018
